Key takeaways from ISPOR Europe 2023

Key takeaways from ISPOR Europe 2023

ISPOR Europe was the busiest we’ve ever seen it. Those few days were jam-packed with engaging plenary sessions, educational symposia, poster research, and networking opportunities. Many fruitful conversations were had, with the team contributing the following rundown...
The power of trial interviews

The power of trial interviews

In October 2023, the US Food and Drug Administration (FDA) released their industry guidance for benefit-risk assessment of novel products¹, in which the role of patient experience data was highlighted in its capacity to “inform nearly every aspect of FDA’s...
Below the surface: NICE’s quality standards in skin cancer

Below the surface: NICE’s quality standards in skin cancer

The National Institute for Health and Care Excellence (NICE) is developing guidance to update the quality standard in skin cancer, which covers the prevention, assessment, diagnosis, and management of malignant and non-malignant melanoma. The draft quality standard is...
Skip to content